Author: | Traci Medford-Rosow | ISBN: | 9781310900198 |
Publisher: | Pegasus Books | Publication: | December 11, 2015 |
Imprint: | Smashwords Edition | Language: | English |
Author: | Traci Medford-Rosow |
ISBN: | 9781310900198 |
Publisher: | Pegasus Books |
Publication: | December 11, 2015 |
Imprint: | Smashwords Edition |
Language: | English |
Replete with intrigue, Inflection Point is the true story of the author and her legal team at Pfizer who found themselves at the epicenter of the decade long, world-wide, multi-billion battle for control over the world’s most prescribed pharmaceutical product, Lipitor®. The author charts the course of the team’s courageous effort to protect the company’s most prized asset, and the unforeseen personal consequences suffered as a result.
In New York, London, Paris, Copenhagen, and Ottawa, from the White House to Wall Street, in boardrooms and courtrooms, in the media and behind closed doors, critical disputes are won and lost in a struggle for survival.
Inflection Point is a fast-paced, high-stakes legal thriller and memoir. But it is also a cautionary tale posing a question as fundamental as it is critical: Have the efforts to bring affordable medicines to consumers helped to cripple the very industry that invents life-saving drugs in the first place?
Replete with intrigue, Inflection Point is the true story of the author and her legal team at Pfizer who found themselves at the epicenter of the decade long, world-wide, multi-billion battle for control over the world’s most prescribed pharmaceutical product, Lipitor®. The author charts the course of the team’s courageous effort to protect the company’s most prized asset, and the unforeseen personal consequences suffered as a result.
In New York, London, Paris, Copenhagen, and Ottawa, from the White House to Wall Street, in boardrooms and courtrooms, in the media and behind closed doors, critical disputes are won and lost in a struggle for survival.
Inflection Point is a fast-paced, high-stakes legal thriller and memoir. But it is also a cautionary tale posing a question as fundamental as it is critical: Have the efforts to bring affordable medicines to consumers helped to cripple the very industry that invents life-saving drugs in the first place?